Priyanka Raheja: Sharing the Final Analysis From the Roctavian Phase 1/2 Study
Priyanka Raheja, Director at The Royal London Hospital Haemophilia Comprehensive Care Centre, shared EAHAD’s post on LinkedIn about a recent article she and her colleagues co-authored, published in Haemophilia Journal, adding:
“Sharing the final analysis from the Roctavian phase 1/2 study.
Despite the sad news of market withdrawal, the long term follow up of the first people who participated in this trial continues to provide important learnings.”
European Association for Haemophilia and Allied Disorders (EAHAD) shared a post on LinkedIn:
“Check the article recently published on our official journal on ‘Final Analysis of the Phase 1/2 Trial of Valoctocogene Roxaparvovec for Severe Haemophilia A’.
Take a closer look at the data on the Haemophilia Journal.”
Title: Final Analysis of the Phase 1/2 Trial of Valoctocogene Roxaparvovec for Severe Haemophilia A
Authors: Priyanka Raheja, Savita Rangarajan, Will Lester, Bella Madan, Glenn F. Pierce, Emily Symington, Carolyn Millar, Dane Osmond, Mingjin Li, Konstantia-Maria Chavele
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 4, 2026, 13:54Ahmad G. Alzahrani: A New Classification for Acute Pulmonary Embolism
-
Sep 4, 2026, 12:52James P. Crowley: MDS vs MPN – Understanding the Difference
-
Sep 4, 2026, 12:02Khalid Abdelsamea Mohamedahmed: Routine Blood Parameters in Pediatric Sickle Cell Anemia
-
Sep 4, 2026, 11:37Consuela A. Albright: The Power of Community Advocacy in Sickle Cell Disease
-
Sep 4, 2026, 11:18Aanika Roshni: When Blood, Biology, and Mechanics Intersect
-
Sep 4, 2026, 10:01Ifeanyichukwu Ifechidere: Making Coagulation Simpler and More Practical
-
Sep 4, 2026, 09:49Omid Khalafi: When the ‘Rules of Three’ Break – What Is Really Happening?
-
Sep 4, 2026, 09:27Hilly Paige: What ESC 2026 Taught Us About LDL-C Management
-
Sep 4, 2026, 05:38Faizan Khan: Why Common Exposures Matter in VTE Risk